No Data
No Data
No Data
No Data
No Data
What Makes Aptose Biosciences (APTO) a New Buy Stock
Yahoo FinanceApr 6 00:00
Aptose Biosciences Is Maintained at Overweight by Piper Sandler
Aptose Biosciences Is Maintained at Overweight by Piper Sandler
Dow JonesApr 4 00:09
Piper Sandler Maintains Overweight on Aptose Biosciences, Maintains $5 Price Target
Piper Sandler analyst Edward Tenthoff maintains Aptose Biosciences (NASDAQ:APTO) with a Overweight and maintains $5 price target.
BenzingaApr 3 23:58
Aptose Biosciences' Strategic Shift to Front-Line AML Therapy Garners Buy Rating
TipRanksMar 28 05:05
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
Yahoo FinanceMar 27 20:26
Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.
Aptose Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 27 18:32
No Data
No Data